Setting the standards for cryopreservation of stem cells for clinical applications

In by

Spotlight Article

Interview

Latest Advances in Addressing Biopreservation Challenges

Glyn Stacey

GS

Glyn Stacey has a background in microbiology and cancer research and has worked on the development of cell substrates for manufacture of biological medicines for over eighteen years. He is currently at the National Institute for Biological Standards and Control which is a part of the Medicines and Healthcare Products Regulatory Agency. He is Director for the UK Stem Cell Bank (UKSCB). The UKSCB has been a licensed clinical tissue bank since 2004. The work of his group has covered safety and quality issues in cell therapy, cells used for manufacturing purposes, development of novel cell-based assays and the development of reference materials for tissue typing and diagnosis of genetic disorders. This work includes the need for scale up of preservation techniques and long-term storage of DNA and cell lines of various types including human stem cell lines and cells used in bioassays and vaccine production. Glyn has served on numerous steering groups for organizations promoting and funding regenerative medicine. He has also chaired the UK National Clinical hESC Forum and the scientific advisory board for a Public Private Partnership not-for-profit company called Stem Cells for Safer Medicine.

DOI: 10.18609/cgti.2017.036
Citation: Cell Gene Therapy Insights 2017; 3(5), 385-388.
Open access

This content is restricted to registered users. Click here to Register or Login here.